Skip to main content

Advertisement

SpringerLink
Log in

Predictive value of pretreatment positron emission tomography/computed tomography in patients with newly diagnosed extranodal natural killer/T-cell lymphoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The role of 18Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) in extranodal natural killer/T-cell lymphoma (ENKL) is not well established. This study aimed to investigate the prognostic role of the pretreatment maximum standardized uptake value (SUVmax) on PET/CT in patients with newly diagnosed ENKL. Among 364 consecutive patients with newly diagnosed ENKL, 81 patients were included and reviewed. The impact of SUVmax on survival and the relationship between SUVmax and other clinicopathological parameters were analyzed. The median SUVmax was 14.6 (range 2.0–45.4). The optimal cutoff value of SUVmax to predict overall survival (OS) was 15. Patients with high SUVmax (SUVmax >15) were associated with bulky disease (P < 0.001), local invasion (P = 0.030), high score of Korean Prognostic Index (KPI, P = 0.046), resistance to primary treatment (P = 0.014), poor OS (P < 0.001), and unfavorable progression-free survival (P < 0.001). With a median follow-up of 25.0 months, the median OS was 63.0 months (range 2.0–99.0 months). Multivariate analyses revealed the following independent prognostic factors for OS: age >60 years (P = 0.001), stage III–IV (P = 0.023), SUVmax >15 (P = 0.020), and bulky disease (>5 cm) (P = 0.002). By using the SUVmax, patients in most subgroups stratified by the KPI or the International Prognostic Index (IPI) were further discriminated in OS with significant statistical difference. Our results suggest the pretreatment SUVmax is predictive of prognosis in patients with newly diagnosed ENKL. The SUVmax may provide additional prognostic information for IPI and KPI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Aozasa K, Ohsawa M, Tajima K, et al. Nation-wide study of lethal mid-line granuloma in Japan: frequencies of wegener’s granulomatosis, polymorphic reticulosis, malignant lymphoma and other related conditions. Int J Cancer. 1989;44(1):63–6.

    Article  PubMed  CAS  Google Scholar 

  2. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–30.

    Article  PubMed  Google Scholar 

  3. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17(12):3835–49.

    PubMed  CAS  Google Scholar 

  4. Jaffe ES, Chan JK, Su IJ, et al. Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol. 1996;20(1):103–11.

    Article  PubMed  CAS  Google Scholar 

  5. Lee J, Kim WS, Park YH, et al. Nasal-type NK/T cell lymphoma: clinical features and treatment outcome. Br J Cancer. 2005;92(7):1226–30.

    Article  PubMed  CAS  Google Scholar 

  6. Lee J, Park YH, Kim WS, et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer. 2005;41(10):1402–8.

    Article  PubMed  Google Scholar 

  7. Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103(1):216–21.

    Article  PubMed  CAS  Google Scholar 

  8. Lim ST, Hee SW, Quek R, et al. Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis. Eur J Haematol. 2008;80(1):55–60.

    PubMed  Google Scholar 

  9. Oshimi K, Kawa K, Nakamura S, et al. NK-cell neoplasms in Japan. Hematology. 2005;10(3):237–45.

    Article  PubMed  Google Scholar 

  10. Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24(4):612–8.

    Article  PubMed  Google Scholar 

  11. Kim TM, Lee SY, Jeon YK, et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol. 2008;19(8):1477–84.

    Article  PubMed  CAS  Google Scholar 

  12. Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009;113(17):3931–7.

    Article  PubMed  CAS  Google Scholar 

  13. Au WY, Pang A, Choy C, et al. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004;104(1):243–9.

    Article  PubMed  CAS  Google Scholar 

  14. Kim SJ, Kim BS, Choi CW, et al. Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Ann Oncol. 2007;18(8):1382–7.

    Article  PubMed  CAS  Google Scholar 

  15. Lee J, Suh C, Huh J, et al. Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type. Clin Cancer Res. 2007;13(11):3250–4.

    Article  PubMed  CAS  Google Scholar 

  16. Yasuda H, Sugimoto K, Imai H, et al. Expression levels of apoptosis-related proteins and Ki-67 in nasal NK/T-cell lymphoma. Eur J Haematol. 2009;82(1):39–45.

    Article  PubMed  Google Scholar 

  17. Juweid ME, Hoekstra OS. Positron emission tomography. New York: Humana Press; 2011.

    Book  Google Scholar 

  18. Cronin CG, Swords R, Truong MT, et al. Clinical utility of PET/CT in lymphoma. AJR Am J Roentgenol. 2010;194(1):W91–103.

    Article  PubMed  Google Scholar 

  19. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86.

    Article  PubMed  Google Scholar 

  20. Juweid ME, Cheson BD. Role of positron emission tomography in lymphoma. J Clin Oncol. 2005;23(21):4577–80.

    Article  PubMed  Google Scholar 

  21. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571–8.

    Article  PubMed  Google Scholar 

  22. Kelloff GJ, Sullivan DM, Wilson W, et al. FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol. 2007;14(3):330–9.

    Article  PubMed  Google Scholar 

  23. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110(10):3507–16.

    Article  PubMed  CAS  Google Scholar 

  24. Ahmadzadehfar H, Rodrigues M, Zakavi R, et al. Prognostic significance of the standardized uptake value of pre-therapeutic (18)F-FDG PET in patients with malignant lymphoma. Med Oncol. 2011;28(4):1570–6.

    Article  PubMed  CAS  Google Scholar 

  25. Chihara D, Oki Y, Onoda H, et al. High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. Int J Hematol. 2011;93(4):502–8.

    Article  PubMed  Google Scholar 

  26. Fujiwara H, Maeda Y, Nawa Y, et al. The utility of positron emission tomography/computed tomography in the staging of extranodal natural killer/T-cell lymphoma. Eur J Haematol. 2011;87(2):123–9.

    Article  PubMed  Google Scholar 

  27. Kako S, Izutsu K, Ota Y, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol. 2007;18(10):1685–90.

    Article  PubMed  CAS  Google Scholar 

  28. Karantanis D, Subramaniam RM, Peller PJ, et al. The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. Clin Lymphoma Myeloma. 2008;8(2):94–9.

    Article  PubMed  Google Scholar 

  29. Chan WK, Au WY, Wong CY, et al. Metabolic activity measured by F-18 FDG PET in natural killer-cell lymphoma compared to aggressive B- and T-cell lymphomas. Clin Nucl Med. 2010;35(8):571–5.

    Article  PubMed  Google Scholar 

  30. Suh C, Kang YK, Roh JL, et al. Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck. J Nucl Med. 2008;49(11):1783–9.

    Article  PubMed  Google Scholar 

  31. Kim TM, Park YH, Lee SY, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood. 2005;106(12):3785–90.

    Article  PubMed  CAS  Google Scholar 

  32. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39(4):561–77.

    PubMed  CAS  Google Scholar 

  33. Dickinson M, Hoyt R, Roberts AW, et al. Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. Br J Haematol. 2010;150(1):39–45.

    PubMed  Google Scholar 

  34. Horning SJ, Juweid ME, Schoder H et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010;115(4):775–777; quiz 918.

    Google Scholar 

  35. Mikhaeel NG, Hutchings M, Fields PA, et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16(9):1514–23.

    Article  PubMed  CAS  Google Scholar 

  36. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25(24):3746–52.

    Article  PubMed  CAS  Google Scholar 

  37. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107(1):52–9.

    Article  PubMed  CAS  Google Scholar 

  38. Hutchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16(7):1160–8.

    Article  PubMed  CAS  Google Scholar 

  39. de Wit M, Bohuslavizki KH, Buchert R, et al. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin’s lymphoma. Ann Oncol. 2001;12(1):29–37.

    Article  PubMed  Google Scholar 

  40. Cheung MM, Chan JK, Lau WH, et al. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys. 2002;54(1):182–90.

    Article  PubMed  Google Scholar 

  41. You JY, Chi KH, Yang MH, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol. 2004;15(4):618–25.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Ya-Rui Zhang for her excellent support on data collection.

Conflict of interest

We declare that we have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, People’s Republic of China

    Bing Bai, Hui-Qiang Huang, Xiao-Xiao Wang, Yan Gao, Qing-Qing Cai, Wen-Qi Jiang & Tong-Yu Lin

  2. State Key Laboratory of Oncology in South China, 651 Dongfeng East Road, Guangzhou, 510060, People’s Republic of China

    Bing Bai, Hui-Qiang Huang, Wei Fan, Xiao-Xiao Wang, Xu Zhang, Yan Gao, Yun-Fei Xia, Ying Guo, Qing-Qing Cai, Wen-Qi Jiang & Tong-Yu Lin

  3. Sun Yat-sen Institute of Hematology, 651 Dongfeng East Road, Guangzhou, 510060, People’s Republic of China

    Bing Bai, Hui-Qiang Huang, Xiao-Xiao Wang, Yan Gao, Qing-Qing Cai, Wen-Qi Jiang & Tong-Yu Lin

  4. Department of Oncology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, People’s Republic of China

    Qi-Chun Cai

  5. Department of Nuclear Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, People’s Republic of China

    Wei Fan & Xu Zhang

  6. Department of Medical Oncology, The Third Affiliated Hospital of Sun Yat-sen University, 600 Tian He Road, Guangzhou, 510630, People’s Republic of China

    Ze-Xiao Lin

  7. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, People’s Republic of China

    Yun-Fei Xia

  8. Clinical Trials Center, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, People’s Republic of China

    Ying Guo

Authors
  1. Bing Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hui-Qiang Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qi-Chun Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiao-Xiao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ze-Xiao Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yan Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yun-Fei Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ying Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Qing-Qing Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Wen-Qi Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Tong-Yu Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hui-Qiang Huang.

Additional information

Bing Bai, Hui-Qiang Huang and Qi-Chun Cai contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bai, B., Huang, HQ., Cai, QC. et al. Predictive value of pretreatment positron emission tomography/computed tomography in patients with newly diagnosed extranodal natural killer/T-cell lymphoma. Med Oncol 30, 339 (2013). https://doi.org/10.1007/s12032-012-0339-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-012-0339-0

Keywords

Search

Navigation